Bayer Reports Topline Data from P-III (OASIS 4) Study of Elinzanetant to Treat Vasomotor Symptoms (VMS) Associated with Breast Cancer Therapies
Shots:
- The P-III (OASIS 4) study assessed elinzanetant (oral, QD) vs PBO for 52wks. to treat mod. to sev. VMS caused by endocrine therapy in women (n=474) & for another 2yrs. for those with or at high risk of HR+ breast cancer
- The study achieved its 1EP of VMS severity reduction at 4 & 12wks., 2EP of reduced VMS frequency at 1wk. & sustained effects, plus improved sleep & menopause-related quality of life at 12wks. The safety remained consistent
- Elinzanetant (NK-1 & 3 antagonist) is a non-hormonal treatment for VMS caused by menopause or adj. endocrine therapy & was subjected to 4 P-III studies (OASIS 1, 2, 3 & 4). Regulatory filings are underway in the US, EU, & other markets
Ref: Bayer | Image: Bayer
Related News:- Bayer Reports the US FDA’s sNDA Acceptance of Nubeqa (Darolutamide) to Treat Metastatic Hormone-Sensitive Prostate Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
